Francisco Adrián

3.3k total citations
30 papers, 1.7k citations indexed

About

Francisco Adrián is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Francisco Adrián has authored 30 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 11 papers in Genetics and 8 papers in Molecular Biology. Recurrent topics in Francisco Adrián's work include Chronic Myeloid Leukemia Treatments (9 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Francisco Adrián is often cited by papers focused on Chronic Myeloid Leukemia Treatments (9 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Francisco Adrián collaborates with scholars based in United States, France and Switzerland. Francisco Adrián's co-authors include Nathanael S. Gray, Markus Warmuth, Gang Xia, Taebo Sim, Yi Liu, Xiang-ju Gu, Sung Joon Kim, Qiang Ding, Guobao Zhang and Jürgen Mestan and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Blood.

In The Last Decade

Francisco Adrián

30 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Francisco Adrián United States 15 714 413 386 339 275 30 1.7k
Sha Jin United States 13 1.6k 2.3× 296 0.7× 620 1.6× 110 0.3× 227 0.8× 30 2.2k
Lisa Roberts United States 9 1.4k 2.0× 205 0.5× 617 1.6× 85 0.3× 223 0.8× 20 1.9k
Mohammad Azam United States 18 694 1.0× 856 2.1× 318 0.8× 77 0.2× 664 2.4× 36 1.6k
Ramadevi Nimmanapalli United States 20 1.3k 1.9× 747 1.8× 443 1.1× 134 0.4× 396 1.4× 35 2.0k
Astrid M. Kral United States 18 2.5k 3.5× 137 0.3× 415 1.1× 237 0.7× 82 0.3× 22 2.9k
Davide Genini United States 19 799 1.1× 137 0.3× 442 1.1× 192 0.6× 324 1.2× 24 1.7k
Deborah DeRyckere United States 30 1.1k 1.5× 237 0.6× 586 1.5× 80 0.2× 129 0.5× 104 3.0k
Gerhard Dürnberger Austria 15 1.4k 2.0× 294 0.7× 212 0.5× 74 0.2× 193 0.7× 26 2.2k
Anna Scuto United States 19 1.4k 2.0× 301 0.7× 667 1.7× 69 0.2× 192 0.7× 30 2.2k
Rekha Rao United States 25 1.8k 2.5× 506 1.2× 401 1.0× 68 0.2× 281 1.0× 49 2.2k

Countries citing papers authored by Francisco Adrián

Since Specialization
Citations

This map shows the geographic impact of Francisco Adrián's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francisco Adrián with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francisco Adrián more than expected).

Fields of papers citing papers by Francisco Adrián

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francisco Adrián. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francisco Adrián. The network helps show where Francisco Adrián may publish in the future.

Co-authorship network of co-authors of Francisco Adrián

This figure shows the co-authorship network connecting the top 25 collaborators of Francisco Adrián. A scholar is included among the top collaborators of Francisco Adrián based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francisco Adrián. Francisco Adrián is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Okuda, Makoto, Morvarid Moayeri, France Pirenne, et al.. (2022). Anti‐CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping. Transfusion. 62(11). 2334–2348. 10 indexed citations
3.
Wang, Anlai, Zhili Song, Gang Zheng, et al.. (2021). Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia. Molecular Cancer Therapeutics. 20(10). 1916–1925. 11 indexed citations
4.
Song, Zhili, Olivier Bedel, Bailin Zhang, et al.. (2021). Abstract 1888: Anti-CD38 interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping. Cancer Research. 81(13_Supplement). 1888–1888. 1 indexed citations
5.
Zhu, Chen, Zhili Song, Anlai Wang, et al.. (2020). Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells. Frontiers in Immunology. 11. 1771–1771. 85 indexed citations
6.
Wei, Shuo, Guang Yang, Juying Li, et al.. (2020). Abstract 2282: Discovery and characterization of novel TNFR2 antibodies to modulate T cell activities in immunosuppressive environment. Cancer Research. 80(16_Supplement). 2282–2282. 1 indexed citations
7.
8.
Wang, Anlai, Rita Greco, Zhifang Li, et al.. (2014). Combination of PIM and JAK2 inhibitors synergistically suppresses cell proliferation and overcomes drug resistance of myeloproliferative neoplasms. Oncotarget. 5(10). 3362–3374. 24 indexed citations
9.
10.
Dierks, Christine, Francisco Adrián, Paul Fisch, et al.. (2010). The ITK-SYK Fusion Oncogene Induces a T-Cell Lymphoproliferative Disease in Mice Mimicking Human Disease. Cancer Research. 70(15). 6193–6204. 51 indexed citations
11.
Deng, Xianming, A. S. Nagle, Tao Wu, et al.. (2010). Discovery of novel 1H-imidazol-2-yl-pyrimidine-4,6-diamines as potential antimalarials. Bioorganic & Medicinal Chemistry Letters. 20(14). 4027–4031. 18 indexed citations
12.
Fabbro, Doriano, Paul W. Manley, Wolfgang Jahnke, et al.. (2010). Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1804(3). 454–462. 47 indexed citations
13.
Choi, Hwan Geun, Pingda Ren, Francisco Adrián, et al.. (2010). A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl. Journal of Medicinal Chemistry. 53(15). 5439–5448. 58 indexed citations
14.
Wu, Tao, A. S. Nagle, Tomoyo Sakata, et al.. (2009). Cell-based optimization of novel benzamides as potential antimalarial leads. Bioorganic & Medicinal Chemistry Letters. 19(24). 6970–6974. 11 indexed citations
15.
Plouffe, David, Achim Brinker, Case W. McNamara, et al.. (2008). In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proceedings of the National Academy of Sciences. 105(26). 9059–9064. 325 indexed citations
16.
Warmuth, Markus, Sung Joon Kim, Xiang-ju Gu, Gang Xia, & Francisco Adrián. (2006). Ba/F3 cells and their use in kinase drug discovery. Current Opinion in Oncology. 19(1). 55–60. 153 indexed citations
17.
Barun, Okram, A. S. Nagle, Francisco Adrián, et al.. (2006). A General Strategy for Creating “Inactive-Conformation” Abl Inhibitors. Chemistry & Biology. 13(7). 779–786. 124 indexed citations
18.
Adrián, Francisco, Qiang Ding, Taebo Sim, et al.. (2006). Allosteric inhibitors of Bcr-abl–dependent cell proliferation. Nature Chemical Biology. 2(2). 95–102. 290 indexed citations
19.
Lefebvre, Sophie, Sonia Berrih‐Aknin, Francisco Adrián, et al.. (2001). A Specific Interferon (IFN)-stimulated Response Element of the Distal HLA-G Promoter Binds IFN-regulatory Factor 1 and Mediates Enhancement of This Nonclassical Class I Gene by IFN-β. Journal of Biological Chemistry. 276(9). 6133–6139. 99 indexed citations
20.
Lefebvre, Sophie, Francisco Adrián, Philippe Moreau, et al.. (2000). Modulation of HLA-G expression in human thymic and amniotic epithelial cells. Human Immunology. 61(11). 1095–1101. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sha Jin Breakdown of academic impact, for papers by Lisa Roberts Breakdown of academic impact, for papers by Mohammad Azam Breakdown of academic impact, for papers by Ramadevi Nimmanapalli Breakdown of academic impact, for papers by Astrid M. Kral Breakdown of academic impact, for papers by Davide Genini Breakdown of academic impact, for papers by Deborah DeRyckere Breakdown of academic impact, for papers by Gerhard Dürnberger Breakdown of academic impact, for papers by Anna Scuto Breakdown of academic impact, for papers by Rekha Rao
Rankless by CCL
2026